Research location
Waterloo
Iowa, United States
Advertisement
Research activity in Waterloo
Iowa, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 123 trials and 135 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Waterloo
123 linked trials · page 1 of 3A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
CHAMP Lung Cancer Screening ProgramNCT07572773 · 2026-06-12 · 2 site observations
RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).NCT07602582 · 2026-05-22 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · 2026-02-09 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation
RECRUITING
Tenapanor in Synucleinopathy-Related ConstipationNCT06460038 · 2025-01-01 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 1 site observation
RECRUITING
Integrated Cancer Repository for Cancer ResearchNCT02012699 · 2013-11-01 · 1 site observation
RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)NCT05463731 · 2022-08-01 · 1 site observation
COMPLETED
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)NCT04437511 · 2020-06-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote MonitoringNCT04292275 · 2020-03-06 · 1 site observation
TERMINATED
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerNCT03793179 · 2019-04-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1NCT03743051 · 2019-03-05 · 1 site observation
COMPLETED
Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502NCT03609021 · 2019-02-26 · 1 site observation
TERMINATED
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)NCT03725059 · 2018-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Dissemination of the Cardiovascular Risk ServiceNCT03660631 · 2018-09-27 · 1 site observation
UNKNOWN
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation
TERMINATED
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung CancerNCT03382912 · 2018-03-22 · 1 site observation
TERMINATED
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeNCT03473223 · 2018-03-21 · 1 site observation
COMPLETED
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerNCT03382899 · 2018-03-19 · 1 site observation
TERMINATED
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyNCT03332771 · 2017-12-01 · 1 site observation
COMPLETED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesNCT02595905 · 2016-09-15 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
PALbociclib CoLlaborative Adjuvant StudyNCT02513394 · 2015-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
MEDication Focused Outpatient Care for Underutilization of Secondary PreventionNCT02215408 · 2015-01-20 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02352948 · 2015-01-13 · 1 site observation
COMPLETED
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01 · 1 site observation
COMPLETED
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01 · 1 site observation
COMPLETED
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01 · 1 site observation
COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31 · 1 site observation
COMPLETED
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08 · 1 site observation
COMPLETED
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16 · 1 site observation
TERMINATED
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT02125461 · 2014-05-07 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02087423 · 2014-02-25 · 1 site observation
COMPLETED
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMNCT02058147 · 2014-02-01 · 1 site observation
COMPLETED
Dimethyl Fumarate (DMF) Observational StudyNCT02047097 · 2013-11-19 · 1 site observation
COMPLETED
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)NCT01897532 · 2013-07-10 · 1 site observation
COMPLETED
Improving Mood in Assisted Living SettingsNCT01763216 · 2013-02-01 · 1 site observation
COMPLETED
NOLAN: Naproxen or Loratadine and NeulastaNCT01712009 · 2012-11-01 · 1 site observation
COMPLETED
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationNCT01682863 · 2012-10-01 · 1 site observation
COMPLETED
Afatinib Expanded Access ProgramNCT01649284 · 2012-07-01 · 1 site observation
APPROVED_FOR_MARKETING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.